1247859-37-5 Usage
Description
1-((3-fluorophenyl)carbamoyl)cyclopropane-1-carboxylic acid is a chemical compound with the molecular formula C12H11FNO3. It is a cyclopropane derivative that contains a carbamoyl group and a 3-fluorophenyl group. This carboxylic acid is likely to have pharmaceutical applications due to its structural features. The presence of the fluorophenyl and carbamoyl groups in the molecule suggests potential biological activity, and further research may be warranted to investigate its potential uses in medical and pharmaceutical applications.
Uses
Used in Pharmaceutical Applications:
1-((3-fluorophenyl)carbamoyl)cyclopropane-1-carboxylic acid is used as a chemical compound for its potential pharmaceutical applications. The presence of the fluorophenyl and carbamoyl groups in the molecule suggests that it may have biological activity, making it a candidate for further research and development in the medical and pharmaceutical industries.
Used in Research and Development:
1-((3-fluorophenyl)carbamoyl)cyclopropane-1-carboxylic acid is used as a research compound for investigating its potential biological activity and possible applications in the medical and pharmaceutical fields. The structural features of this compound, including the carbamoyl and 3-fluorophenyl groups, may provide valuable insights into its interactions with biological systems and its potential as a therapeutic agent.
Used in Drug Design and Synthesis:
1-((3-fluorophenyl)carbamoyl)cyclopropane-1-carboxylic acid is used as a building block or starting material in the design and synthesis of new drugs. Its unique structural features, including the cyclopropane ring, carbamoyl group, and 3-fluorophenyl group, may be exploited to create novel drug candidates with improved pharmacological properties and therapeutic potential.
Used in Chemical Synthesis:
1-((3-fluorophenyl)carbamoyl)cyclopropane-1-carboxylic acid is used as an intermediate in the synthesis of various chemical compounds. Its versatile structure allows for further functionalization and modification, making it a valuable precursor in the preparation of a wide range of chemical products, including pharmaceuticals, agrochemicals, and specialty chemicals.
Check Digit Verification of cas no
The CAS Registry Mumber 1247859-37-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,4,7,8,5 and 9 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1247859-37:
(9*1)+(8*2)+(7*4)+(6*7)+(5*8)+(4*5)+(3*9)+(2*3)+(1*7)=195
195 % 10 = 5
So 1247859-37-5 is a valid CAS Registry Number.
1247859-37-5Relevant articles and documents
Synthesis and anti-tumor activity of [1,4] dioxino [2,3-f] quinazoline derivatives as dual inhibitors of c-Met and VEGFR-2
Wei, Dengshuai,Fan, Haoru,Zheng, Kun,Qin, Xuemei,Yang, Leifu,Yang, Yajuan,Duan, Ye,Zhang, Qiang,Zeng, Chengchu,Hu, Liming
, (2019/04/27)
Both c-Met and VEGFR-2 were important targets for cancer therapies. In order to develop reversible and non-covalent c-Met and VEGFR-2 dual inhibitors, a series of [1,4]dioxino[2,3-f]quinazoline derivatives were designed and synthesized. The enzyme assay demonstrated that most target compounds had inhibition potency on both c-Met and VEGFR-2 with IC50 values in nanomolar range especially compounds 7m and 7k. Based on further cell proliferation assay in vitro, compound 7k showed significantly anti-tumor activity in vivo on a hepatocellular carcinoma (MHCC97H cells) xenograft mouse model. We docked the compound 7m with c-Met and VEGFR-2 kinases, and interpreted the SAR of these analogues. All results indicated that the target compounds were dual inhibitors of c-Met and VEGFR-2 kinases that held promising potential in cancer therapy.
c-Met small-molecule inhibitor, pharmaceutical composition containing same and pharmaceutical application of pharmaceutical composition containing same
-
Paragraph 0061; 0062; 0063; 0064, (2017/04/07)
The invention provides a c-Met small-molecule inhibitor, a preparation method thereof, a pharmaceutical composition containing derivatives, salts of the pharmaceutical composition and application of medicines with the pharmaceutical composition or salts thereof as active ingredients to preparation of antitumor drugs and drugs for treating diseases relevant to liver diseases. The c-Met small-molecule inhibitor is structurally shown as the general formula (I). The pharmaceutical composition is high in in-vitro tumor inhibiting activity and capable of reaching a nanomole level for c-Me kinase inhibiting activity and can be used as liver cancer treatment drugs novel in structure, thereby being high in commercial value.
Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors
Zhao, Yanmei,Zhang, Jiankang,Zhuang, Rangxiao,He, Ruoyu,Xi, Jianjun,Pan, Xuwang,Shao, Yidan,Pan, Jinming,Sun, Jingjing,Cai, Zhaobin,Liu, Shourong,Huang, Weiwei,Lv, Xiaoqing
, p. 3195 - 3205 (2017/05/25)
In this study, a series of novel pyridine and pyrimidine-containing derivatives were designed, synthesized and biologically evaluated for their c-Met inhibitory activities. In the biological evaluation, half of the target compounds exhibited moderate to p
